Together towards the Future

Happy New Year!

As 2024 comes to a closure, a new chapter begins. In the face of an ever-changing market environment, we have consistently overcome challenges and achieved success. Every breakthrough reflects the perseverance and dedication of our employees and partners, and every accomplishment exemplifies how we illuminate patients' lives through innovation.

2024 marks the first year of the rapidly evolving InnoCare 2.0. We have stayed true to our original aspirations and continue to advance our mission.

This year, our commercialization efforts further accelerated growth, leading us to constantly raise the sales forecast for orelabrutinib. Its new indication for marginal zone lymphoma has showcased significant market potential, driving continued sales momentum. Concurrently, the Company has built a more experienced and capable commercial team for hemato-oncology.

Our unremitting efforts this year have advanced our pipeline, offering hopes to patients for better treatment options. The China National Medical Products Administration (NMPA) accepted and granted priority review to the biologics license application (BLA) for tafasitamab in combination with lenalidomide. Additionally, the new drug application (NDA) of orelabrutinib for the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma was accepted. We anticipate these two approvals next year. We also expect to submit the NDA for zurletrectinib (ICP-723) in the first quarter of next year.

We also made significant progress across six indications in autoimmune diseases this year. Orelabrutinib received U.S. FDA approval to initiate a Phase III clinical trial for the treatment of primary progressive multiple sclerosis. The Phase III clinical trial of ICP-332 for the treatment of atopic dermatitis was initiated, while its new indication for vitiligo received clinical trial approval. Furthermore, the Phase II clinical trial of ICP-488 for psoriasis demonstrated positive results, and plans are underway to begin the Phase III trial soon.

2025 marks the tenth year in InnoCare’s journey. Standing at this new starting point, we remain steadfast in our commitment to outstanding innovation and strong execution.

We must maintain the spirit of entrepreneurship to turn the seemingly impossible into reality. We will accelerate innovation, commercialization and globalization. This is the mission that we must fulfil during the 2.0 stage. We will make concerted efforts to bring five to six innovative drugs to the market in the next three to five years and expand three to four products into global markets, fulfilling the Company's 2.0 goals.

The road to the future will be full of challenges, but I firmly believe that as long as all of us work together with one goal, there will be no difficulties that cannot be overcome. On the journey to illuminate human health, let us remain true to our original aspirations and move towards the future together!

Best wishes to you all for a healthy and happy 2025!